4 results about "Plasma cholesterol" patented technology

The present invention relates to compounds of Table 1, which are encompassed by Formula I and / or Formula II, Ill, IV, V, or VI, and pharmaceutically acceptable salts, solvates or compositions thereof. Compounds of Table 1 are PCSK9 interacting small molecules that modulate PCSK9 activity and significantly increase low density lipoprotein receptor expression and activity, lower total circulating cholesterol and are useful for treating and delaying the onset of diseases that are associated with elevated cholesterol.

The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical compositions which contain therapeutic amount of a pharmaceutically acceptable salt of fluvastatin; hydroxypropyl methyl cellulose; and a non-ionic, hydrophilic polymer selected from the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average molecular weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average molecular weight ranging from 100,000 to 500,000 for the reduction of plasma cholesterol levels.

The present disclosure includes compositions and methods for treating cardiovascular disease (CVD) (e.g., cholesterol related disorders, or diseases caused or characterized by increased levels of plasma triglycerides, plasma cholesterol, or serum C-reactive protein), or symptoms thereof. The disclosure also includes compositions and methods for lowering plasma triglycerides in a subject, lowering plasma cholesterol levels in a subject, and lowering serum C-reactive protein levels in a subject.

The present invention relates to a composition comprising Rhodospirillum rubrum cells for use in a method for inhibiting the uptake of cholesterol from the intestine in a human subject, such that the plasma LDL-cholesterol level in said human subject is lowered and concentrations of blood proteins relating to kidney function, liver function and / or heart function are essentially unaltered. In addition, the invention relates to a non-therapeutic method of lowering plasma LDL-cholesterol level in a subject, the method comprising administering to the subject a composition comprising Rhodospirillum rubrum cells, wherein lowering of the plasma LDL-cholesterol level is the inhibition of the uptake of cholesterol from the intestine in said human subject. Furthermore, the invention relates to a food product, a feed product, a food stuff and a food supplement comprising Rhodospirillum rubrum cells and having plasma LDL-cholesterol level lowering properties relating to intestinal cholesterol uptake inhibitory properties.